What is the Current State of the Antimicrobial Pipeline?
JUN 18, 2016 | CONTAGION EDITORIAL STAFF
John Mohr, PharmD, president and founder of Medical Affairs Strategic Solutions, LLC, explains the current state of the antimicrobial pipeline.
Interview Transcript (slightly modified for readability)
“For over the past 30 years, the antimicrobial pipeline has been declining; however, most recently there have been slight improvements in the number of antibiotics that have come to the market. The majority of the antibiotic classes that we have available today were all discovered before 1960. There have only been two novel classes of antibiotics developed in the past 30 years.
In 2010, the Infectious Disease Society of America (IDSA) called for 10 new antibiotics to be developed by the year 2020, and there have currently been five new antibiotics. However, the majority of those have been for the treatment of gram-positive infections. What we still need is more antibiotics for the management of patients with infections caused by gram-negative bacteria.”
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512